title: Dissecting complement blockade for clinic use.
abstract: In this issue of Blood, Peffault de Latour et al describe ex vivo measurements of complement activity in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab treatment. This is the first systematic pharmacodynamic (PD) study of eculizumab in PNH patients which shows that CH50 is a promising biomarker of therapeutic complement blockade.
authors: FEDERICO II UNIVERSITY.
authors: Antonio M
authors: AM
authors: Risitano
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000493:pharmacokinetics*; D003182:Complement C5 / Q000037:antagonists & inhibitors*; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000493:pharmacokinetics*; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003182:Complement C5; D007155:Immunologic Factors; C481642:eculizumab